Bottom line. CVS’s second quarter strengthened the case that Aetna’s recovery is underway and established a higher normalized 2026 earnings base. However, the preliminary 2027 EPS floor remained in line with pre-print consensus. CVS now defines its 2026 adjusted EPS baseline at $7.46 and offered a preliminary 2027 floor of at least $8.44, implying about 13% growth with only dilution-offsetting repurchases. 13% EPS growth is good, but that floor is almost identical to $8.43 pre-print consensus. CVS shares fell 11% from the August 4 pre-print close through August 27. Aetna’s results improved, reducing risk to 2026 guidance. But expected Caremark membership declines, continued 340B pressure and the absence of a detailed segment bridge did not support 2027 earnings materially above existing consensus. The $2.58 adjusted 2Q26 EPS result remained well above consensus after adjusting for the favorable Health Care Benefits (HCB) items.
2Q26 EPS beat still 24% above consensus after normalization
Reported adjusted EPS of $2.58 beat $1.85 pre-print consensus by 39%. Approximately $500M of HCB adjusted operating income came from the 2025 exchange risk-adjustment update and favorable prior-year development. Applying the 24.9% full-year tax assumption and approximately 1.287B diluted shares produces an estimated $0.29 per-share benefit and a normalized EPS proxy of about $2.29. That is still roughly $0.44, or 24%, above consensus.
The result also had support outside Aetna. Health Services adjusted operating income was $1.7B versus $1.5B consensus. Pharmacy & Consumer Wellness (PCW) produced $1.5B of adjusted operating income versus $1.4B consensus. PCW comparable sales increased 2.6% against a 0.9% expected decline, led by pharmacy. Management said Health Services included an unspecified pull-forward from the second half and that underlying performance was roughly in line with expectations after excluding it. Broader Caremark and specialty-generic strength offset 340B pressure, but the full-year Health Services floor remained at least $7.25B. The segment beats extended beyond HCB, but the Health Services pull-forward and unchanged full-year guidance argue against carrying its full quarterly variance into the second half.
2026 adjusted EPS baseline increased about 3.5%
CVS raised its 2026 adjusted EPS range to $7.90-$8.10 from $7.30-$7.50, moving the midpoint to $8.00 from $7.40. The company then removed $0.54 of known favorable first-half items to establish a $7.46 baseline. The $7.45 pre-print consensus is assumed to have fully incorporated the first-quarter benefit, which Graver Research estimates at approximately $0.25 per share from the disclosed $420M HCB guide increase. Removing that amount creates a derived clean pre-print hurdle of about $7.20. On that like-for-like basis, the current baseline is approximately $0.26, or 3.5%, above the derived $7.20 hurdle, compared with the reported $0.60, or 8.1%, increase in the guidance midpoint.
Sources: CVS Health; StreetAccount; Koyfin; Graver Research calculations.
The higher base has identifiable operating and cash support. HCB’s full-year adjusted operating-income midpoint increased $1.0B to $5.2B, and the PCW floor rose $220M to at least $6.4B. Together they exceed the $1.1B increase in CVS’s enterprise midpoint, implying an approximate $200M offset elsewhere that cannot be assigned cleanly. Health Services adjusted operating-income guidance did not change. After subtracting the known $420M and $500M HCB items, a simple Graver Research proxy puts the HCB guide at $4.28B, about $530M above the 2025 Investor Day midpoint. Operating cash-flow guidance also increased to at least $11.5B from at least $9.5B. The normalized EPS increase has segment and cash-flow support, but the guidance changes remain concentrated in HCB.
HCB remained above consensus after normalization
HCB provides the quarter’s strongest evidence. Reported adjusted operating income of $2.4B was far above $1.5B consensus. Removing all $500M of disclosed favorable items leaves a proxy of approximately $1.9B, still $466M, or 32%, ahead of consensus. The same test holds for the medical benefit ratio. Reported MBR of 87.4% was 240 bps favorable to 89.8% consensus; adding back the disclosed 140 bps benefit produces an 88.8% normalized proxy, still 100 bps favorable.
Sources: CVS Health; StreetAccount; Graver Research calculations.
Neither the reported nor normalized second-quarter MBR should be treated as a second-half run rate. First-half HCB adjusted operating income rose 66% to $5.5B, but the comparison includes far fewer premium-deficiency reserve (PDR) charges. The second quarter of 2025 contained a $471M group Medicare Advantage PDR, and first-half 2025 health-care-cost PDR components totaled $902M versus a new $15M Medicaid PDR in first-half 2026. Management also expects HCB MBR to rise slightly more than 950 bps from the adjusted first-quarter level to the fourth quarter. About 75% of the group MA book had been renewed or priced, and 2027 bids assume continued elevated trend. Pricing, Medicare mix and medical-cost execution support the recovery case, but the PDR comparison and expected second-half MBR increase leave normalized earnings power unproven.
Caremark is the main constraint on 2027 upside
Caremark is the main constraint on upside to the preliminary 2027 EPS floor. CVS secured more than $6B of new sales in the prior selling season, above its historical average, and described 2027 retention as slightly below its own history but closer to industry norms. At the same time, management identified two sources of membership loss: contracts CVS chose not to retain as it shifted toward lowest-net-cost models, and health-plan customer product actions or market exits. CVS did not quantify net membership, the related adjusted operating-income effect, the timing of new business or the 340B headwind. The unchanged Health Services floor and unsized second-quarter pull-forward further limit the earnings read-through from the quarterly beat. The lack of upside to the $8.44 floor is more closely tied to unresolved Caremark retention and economics than to Aetna.
Specialty pharmacy, the 2027 generic pipeline, biosimilars and Cordavis, PCW, and further delivery execution provide offsets. The $8.44 floor also assumes only dilution-offsetting repurchases. While the FTC agreement reduces one source of legal uncertainty, it still does not create needed certainty about 2027. Announced before the print, the FTC consent package had been accepted for public comment but is still not a final order. Proposed terms include a standard offering tied more closely to contracted net cost, point-of-sale rebates, limits on list-price-linked compensation, transparency and community-pharmacy protections; custom terms remain possible after disclosure and written acknowledgment. Implementation is staged: some provisions take effect by an implementation date no later than January 1, 2027, while several substantive standard-offering provisions begin January 1, 2028. CVS says much of the work was underway, but it has not quantified implementation costs or the P&L effect. The disclosed offsets support the achievability of $8.44, but CVS has not provided enough Caremark or implementation detail to treat the floor as conservative.
The 11% selloff far exceeded outer-year estimate revisions
CVS rose 30.2% from May 5 through the August 4 pre-print close, compared with 12.1% for XLV. It then fell 5.1% on August 5 and 11.0% through August 27, while XLV gained 5.8%. Over the post-print period, FY26 adjusted EPS consensus increased 6.7%, but FY27 and FY28 rose only 0.9% and 0.6%. CVS materially outperformed XLV before the print and then fell far more than FY27 and FY28 consensus changed. Clearly investors were hoping for more clarity on the second quarter call.
Source: Koyfin.
Source: Koyfin.
CVS is not necessarily cheap: its 11.4x NTM P/E is above its 10.5x ten-year median, but below its 12.2x plus-one-standard-deviation level. First-half operating cash flow of $10.6B less $1.5B of capital spending produces a simple $9.1B free-cash-flow proxy, and CVS repaid $3.3B of debt. CVS’s 3.5x net-debt leverage is down from 4.0x at year-end 2025, although first-half cash benefited from working-capital improvements and should not be annualized. Cash generation and lower leverage reduce balance-sheet risk, but multiple expansion requires operating evidence that 2027 adjusted EPS can exceed $8.44.
The remaining tests are HCB durability and Caremark economics
2Q26 established a higher and more credible $7.46 earnings base. A stronger thesis requires HCB adjusted operating income and MBR to remain better than consensus after favorable items roll off, without new material PDRs. Caremark wins need to offset membership losses at acceptable economics, 340B pressure must be contained or quantified, and formal 2027 segment guidance needs to support a result above the preliminary $8.44 floor. Cash conversion and deleveraging also need to continue. Another strong HCB quarter alone will not clear up the valuation story here; investors need more clarity on Caremark too. Moderate Caremark attrition will not invalidate the thesis if margins and consolidated earnings hold. HCB reversion, new reserve charges, weaker retention or dependence on incremental buybacks would weaken it. Q2 strengthened the Aetna recovery case; 2027 upside still depends on quantified Caremark retention and adjusted operating-income expectations.